Tag: Edwards Lifesciences
EuroPCR 2026: SMART trial three-year data demonstrate superiority for Evolut TAVI system
Medtronic today relea...
Medtech Insights: Edwards’ Brüls outlines company’s move to specialise on structural heart disease
When Cardiovascular N...
Edwards Lifesciences continues acquisition spree, announcing JenaValve and Endotronix deals
Edwards Lifesciences has ...
Transcatheter tricuspid valve repair shows promise for reducing heart failure hospitalisations
In JACC: Heart Failur...
Edwards Lifesciences issues an urgent field safety notice for Centera TAVI system
After receiving repor...
TVT 2019: PASCAL system may be beneficial for managing tricuspid regurgitation
New data for the PASCAL s...
ADVERTORIAL: Edwards PASCAL™ Transcatheter Valve Repair System is innovative
This content is only ...
ACC 2019: TAVI moves to the mainstream with new findings in low-risk patients
Evidence for the use of t...
Boston Scientific, Edwards Lifesciences agree to global litigation settlement
Boston Scientific and Edw...
First implant of Pascal transcatheter mitral valve repair device performed in CLASP IID trial
The first implant of the ...
Enrolment complete in CT imaging substudy of leaflet mobility with Sapien 3 in low-risk patients
Edwards Lifesciences ...
TCT 2017: TMVI in mitral ring is a reasonable alternative for high-risk patients
Data from the MITRAL ...
Edwards Lifesciences’ Alterra adaptive prestent device used for first time to treat a malformed pulmonary valve
Evan Zahn (Guerin Family ...
German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application
The District Court in...
First procedures using Edward Lifesciences’ Inspiris Resilia aortic valve take place
The first ever Inspir...
EuroPCR 2017: Excellent early outcomes for Edwards Lifesciences’ self-expanding valve
According to late-bre...
ACC 2017: Embol-X and CardioGard do not reduce number of brain lesions, but may affect lesion size
Two US Food and Drug Admi...
TCT 2016: Transfemoral TAVI improves quality of life in intermediate-risk patients
Data presented at the...
Sapien 3 now approved for intermediate-risk patients in Europe as well as in the USA
Following last month’...
